Cervical cancer incidence and mortality in the best and worst of worlds

Scandinavian Journal of Public Health

Volumn 34, Issue 3, 2006, Pages 295-303

  Rydström, Catrine ^a   Törnberg, Sven ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cervical cancer; epidemiology; influencing factors; ranking; screening

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; BEHAVIOR; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CONDYLOMA; CONTROLLED STUDY; CULTURAL FACTOR; EARLY DIAGNOSIS; FEMALE; FORECASTING; HABIT; HUMAN; PAPANICOLAOU TEST; PRECANCER; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RISK ASSESSMENT; RISK REDUCTION; TREATMENT OUTCOME; UTERINE CERVIX CANCER;

ADULT; AGED; FEMALE; FORECASTING; HUMANS; INCIDENCE; MASS SCREENING; MIDDLE AGED; MODELS, THEORETICAL; OUTCOME ASSESSMENT (HEALTH CARE); PAPILLOMAVIRIDAE; SWEDEN; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 33744938191     PISSN: 14034948     EISSN: None     Source Type: Journal    
DOI: 10.1080/14034940500241979     Document Type: Article

References (38)

1. IARC CancerBase GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide, Version 1.0. Lyon: IARC Press, 2001.
2. Parkin D.M., Bray F.I., Devesa S.S. Cancer burden in the year 2000. The global picture. Eur J Cancer 37(Suppl. 8):S4-66, October 2001.
3. The National Board of Health and Welfare. Gynekologisk cellprovskontroll. Förslag till screeningprogram (Gynaecological cytotesting. Proposal for a screening programme) (in Swedish). Vol. 15. Sweden: National Board, 1998.
4. Walboomers J.M., Jacobs M.V., Manos M.M., et al. Human papilloma virus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.
5. Holly E.A. Cervical intraepithelial neoplasia, cervical cancer, and HPV. Annu Rev Public Health 1996;17:69-84.
6. Castellsague X., Bosch F.X., Munoz N. Environmental cofactors in HPV carcinogenesis. Virus Res 2002;89:191-9.
7. Kjellberg L., Hallmans G., Ahren A.M., et al. Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papilloma virus infection. Br J Cancer 2000;82:1332-8.
8. Davidson E.J., Kitchener H.C., Stern P.L. The use of vaccines in the prevention and treatment of cervical cancer. Clin Oncol 2002; 14:193-200.
9. Laara E., Day N.E., Hakama M. Trends in mortality from cervical cancer in the Nordic countries: Association with organised screening programmes. Lancet 1987;1:1247-9.
10. Andrae B., Smith P. Clinical impact of quality assurance in an organized cervical screening program. Acta Obstet Gynecol Scand 1999;78:429-435.
11. Sigurdsson K. Effect of organized screening on the risk of cervical cancer. Evaluation of screening activity in Iceland, 1964—1991. Int J Cancer 1993;54:563-570.
12. Gustafsson L., Adami H.O. Cytologic screening for cancer of the uterine cervix in Sweden evaluated by identification and simulation. Br J Cancer 1990;61:903-8.
13. Eaker S., Adami H.-A., Sparén P. Reasons women do not attend screening for cervical cancer: A population-based study in Sweden. Prev Med 2001;32:482-491.
14. Munoz N., Franceschi S., Bosetti C., et al. Role of parity and human papillomavirus in cervical cancer: The IARC multicentric case-control study. Lancet 2002;359:1093-1101.
15. Levi F., Lucchini F., Negri E., Franceschi S., la Vecchia C. Cervical cancer mortality in young women in Europe: patterns and trends. Eur J Cancer 2000;36:2266-2271.
16. Sasieni P., Cuzick J. Could HPV testing become the sole primary cervical screening test? J Med Screen 2002; 9:49-51.
17. Cuzick J. Role of HPV testing in clinical practice. Virus Res 2002;89:263-9.
18. Fylan F. Screening for cervical cancer: a review of women's attitudes, knowledge, and behaviour. Br J Gen Pract 1998;48:1509-1514.
19. Eaker S., Adami H.O., Sparen P. Attitudes to screening for cervical cancer: A population-based study in Sweden. Cancer Causes Control 2001;12:519-528.
20. Neilson A., Jones R.K. Women's lay knowledge of cervical cancer/cervical screening: accounting for non-attendance at cervical screening clinics. J Adv Nurs 1998;28:571-5.
21. Perry M.A. How can the uptake of cervical cytology screening be improved? Nurs Stand 2001;16:33-36.
22. Maxwell C.J., Bancej C.M., Snider J., Vik S.A. Factors important in promoting cervical cancer screening among Canadian women: Findings from the 1996—97 National Population Health Survey (NPHS). Can J Public Health 2001;92:127-133.
23. Forss A., Tishelman C., Widmark C., Lundgren E., Sachs L., Tornberg S. “I got a letter…”: A qualitative study of women's reasoning about attendance in a cervical cancer screening programme in urban Sweden. Psychooncology 2001;10:76-87.
24. Matuk L.C. Pap smear screening practices in newcomer women. Women's Health Issues 1996;6:82-88.
25. Hubbell F.A., Chavez L.R., Mishra S.I., Valdez R.B. Beliefs about sexual behavior and other predictors of Papanicolaou smear screening among Latinas and Anglo women. Arch Intern Med 1996;156:2353-8.
26. Katz S.J., Hofer T.P. Socioeconomic disparities in preventive care persist despite universal coverage: Breast and cervical cancer screening in Ontario and the United States. JAMA 1994;272:530-4.
27. Forss A., Tishelman C., Widmark C., Sachs L. Women's experiences of cervical cellular changes: an unintentional transition from health to liminality? Sociol Health Illn 2004 Apr; 26(3):306-325.
28. Segnan N., Senore C., Giordano L., Ponti A., Ronco G. Promoting participation in a population screening program for breast and cervical cancer: A randomized trial of different invitation strategies. Tumori 1998;84:348-353.
29. Eaker S., Adami H.-O., Granath F., Wilander E., Sparén P. A large population-based randomized controlled trial to increase attendance at screening for cervical cancer. Cancer Epidemiol Biomarkers Prev 2004;3: 346-354.
30. Sasieni P., Adams J., Cuzick J. Benefit of cervical screening at different ages: Evidence from the UK audit of screening histories. Br J Cancer 2003;89:88-93.
31. Recommendations on cancer screening in the European Union: Advisory Committee on Cancer Prevention. Eur J Cancer 2000;36:1473-8.
32. Coleman D., Day N., Douglas G., et al. European Guidelines for Quality Assurance in Cervical Cancer Screening: Europe against cancer programme. Eur J Cancer 1993;29A(Suppl. 4):S1-38.
33. Symonds R.P. Success and failure in screening for cervical cancer. Clin Oncol 1994;6:251-3.
34. Khanna N., Philips M. Adherence to care plan in women with abnormal Papanicolaou smears: A review of barriers and interventions. J Am Board Fam Pract 2001;2:123-130.
35. Von Reibnitz U. Scenario techniques. Hamburg: McGraw-Hill GmbH, 1988.
36. Garland S.M. Human papillomavirus update with a particular focus on cervical disease. Pathology (Phila) 2002;34:213-224.
37. Zetterman K. Hur många ska vaccineras? En modellanalys med utgångspunkt från exemplet kikhostevaccin (How many should get vaccinated? An analytical model with the pertussis vaccine as a starting point). Master essay (in Swedish). Karolinska Institutet, 1997.
38. Paul C., Tzelepis F., Walsh R.A., Girgis A., King L., McKenzie J. Has the investment in public cancer education delivered observable changes in knowledge over the past 10 years? Cancer 2003;97:2931-9.